Top MarketRank™ StocksTop MarketRank™NASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis $111.57 +2.03 (+1.85%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$109.33▼$112.8850-Day Range$100.57▼$114.5352-Week Range$99.06▼$146.70Volume645,145 shsAverage Volume523,790 shsMarket Capitalization$7.04 billionP/E Ratio23.00Dividend YieldN/APrice Target$185.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Jazz Pharmaceuticals alerts: Email Address Jazz Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside66.6% Upside$185.86 Price TargetShort InterestHealthy4.41% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment1.02Based on 9 Articles This WeekInsider TradingSelling Shares$565,989 Sold Last QuarterProj. Earnings Growth17.69%From $15.32 to $18.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.96 out of 5 starsMedical Sector8th out of 936 stocksPharmaceutical Preparations Industry3rd out of 436 stocks 4.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jazz Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.41% of the outstanding shares of Jazz Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 3.73%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 2.8 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Jazz Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 16 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $565,989.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 17.69% in the coming year, from $15.32 to $18.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 23.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 23.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.08.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.68. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Jazz Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More JAZZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAZZ Stock News HeadlinesJuly 25 at 4:05 PM | prnewswire.comJazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General MeetingJuly 23, 2024 | markets.businessinsider.comBuy Rating Upheld for Jazz Pharmaceuticals Amidst Potential for Growth and Strategic RevaluationJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 22, 2024 | prnewswire.comJazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026July 19, 2024 | investorplace.comIf You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 NamesJuly 17, 2024 | prnewswire.comJazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024July 17, 2024 | 247wallst.comAdd These 5 Hot Biotech Stocks In JulyJuly 9, 2024 | prnewswire.comJazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial OfficerJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 4, 2024 | investorplace.com3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their PotentialJuly 1, 2024 | insidermonkey.comIs Jazz Pharmaceuticals plc (JAZZ) the Best Pot Stock to Buy Now?June 25, 2024 | investorplace.com3 Cannabis Stocks That Could Make Your Grandchildren RichJune 21, 2024 | seekingalpha.comJazz Pharmaceuticals: Pipeline Setback While Business Transition ContinuesJune 20, 2024 | reuters.comJazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage studyJune 20, 2024 | prnewswire.comJazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential TremorJune 14, 2024 | investorplace.com3 Blue-Chip Stocks to Triple Your Wealth by 2026: June EditionJune 3, 2024 | investorplace.com7 Overlooked Stocks Offering Long-Term Stability From the ShadowsJune 1, 2024 | prnewswire.comJazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024See More Headlines Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Stock Price Target$185.86 High Stock Price Target$230.00 Low Stock Price Target$113.00 Potential Upside/Downside+66.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$4.85 Trailing P/E Ratio23.00 Forward P/E Ratio7.28 P/E Growth1.67Net Income$414.83 million Net Margins8.61% Pretax Margin6.28% Return on Equity27.86% Return on Assets8.91% Debt Debt-to-Equity Ratio1.38 Current Ratio2.27 Quick Ratio1.90 Sales & Book Value Annual Sales$3.83 billion Price / Sales1.83 Cash Flow$28.53 per share Price / Cash Flow3.91 Book Value$59.36 per share Price / Book1.88Miscellaneous Outstanding Shares63,060,000Free Float60,413,000Market Cap$7.04 billion OptionableOptionable Beta0.58 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Bruce C. Cozadd (Age 60)Co-Founder, Chairman & CEO Comp: $2.44MMs. Heidi Manna (Age 52)Executive VP & Chief People Officer Dr. Jed Black M.D.Senior Vice President of Sleep & CNS MedicineMs. Samantha Pearce (Age 58)Senior Vice President of Europe & International Mr. John MillerSenior Vice President of Corporate StrategyMs. Aislinn DoodyCompany SecretaryDr. Katherine A. LittrellVice President of Investor RelationsMr. Joshua R. Steinerman M.D.Vice President of NeuropsychiatryMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXUltragenyx PharmaceuticalNASDAQ:RAREArrowhead PharmaceuticalsNASDAQ:ARWRACADIA PharmaceuticalsNASDAQ:ACADBausch Health CompaniesNYSE:BHCView All CompetitorsInsiders & InstitutionsAustralianSuper Pty LtdBought 40,302 shares on 7/26/2024Ownership: 0.152%Allspring Global Investments Holdings LLCBought 1,931 shares on 7/26/2024Ownership: 0.029%State of Michigan Retirement SystemSold 2,560 shares on 7/26/2024Ownership: 0.024%AlphaCentric Advisors LLCBought 2,500 shares on 7/26/2024Ownership: 0.017%Patriot Financial Group Insurance Agency LLCSold 2,413 shares on 7/26/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions JAZZ Stock Analysis - Frequently Asked Questions How have JAZZ shares performed this year? Jazz Pharmaceuticals' stock was trading at $123.00 at the beginning of the year. Since then, JAZZ shares have decreased by 9.3% and is now trading at $111.57. View the best growth stocks for 2024 here. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings data on Wednesday, May, 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.53 by $1.55. The specialty pharmaceutical company earned $901.98 million during the quarter, compared to analysts' expectations of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a trailing twelve-month return on equity of 27.86%. What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Jazz Pharmaceuticals: Cavion. Who are Jazz Pharmaceuticals' major shareholders? Top institutional investors of Jazz Pharmaceuticals include Swedbank AB (1.59%), Bank of New York Mellon Corp (0.81%), Retirement Systems of Alabama (0.31%) and AustralianSuper Pty Ltd (0.15%). Insiders that own company stock include Bruce C Cozadd, Neena M Patil, Robert Iannone, Renee D Gala, Kim Sablich, Philip L Johnson, Finbar Larkin, Kenneth W O'keefe, Patrick G Enright, Christopher J Tovey, Peter Gray, Samantha Pearce, Rick E Winningham, Anne Oriordan, Mark Douglas Smith, Patricia Carr, Jennifer E Cook and Elmar Schnee. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX) and Tesla (TSLA). This page (NASDAQ:JAZZ) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
